# MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study

> **NCT03226119** · PHASE4 · COMPLETED · sponsor: **MP Biomedicals, LLC** · enrollment: 150 (actual)

## Conditions studied

- HTLV-I Infections
- HTLV-II Infections
- Human T-lymphotropic Virus 1
- Human T-lymphotropic Virus 2
- HTLV I Associated T Cell Leukemia Lymphoma
- HTLV I Associated Myelopathies

## Interventions

- **DIAGNOSTIC_TEST:** MP Diagnostics HTLV Blot 2.4

## Key facts

- **NCT ID:** NCT03226119
- **Lead sponsor:** MP Biomedicals, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-15
- **Primary completion:** 2018-07-10
- **Final completion:** 2018-08-31
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2018-09-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03226119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03226119, "MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03226119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*